Intellia Therapeutics (STU:38I) Cyclically Adjusted FCF per Share: €-2.98 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:38I Intellia Therapeutics Inc STU:38I
69 GF Score
Price €10.10
GF Value €11.36
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Intellia Therapeutics Cyclically Adjusted FCF per Share?

Intellia Therapeutics STU:38I -1.56% 69 Cyclically Adjusted FCF per Share is €-2.98 as of Jun. 2026. GuruFocus rates STU:38I with a GF Score™ of 69/100 and a GF Value™ of €11.36 (Modestly Undervalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Intellia Therapeutics's adjusted free cash flow per share for the three months ended in Jun. 2026 was €-0.552. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-2.98 for the trailing ten years ended in Jun. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-09-13), Intellia Therapeutics's current stock price is €10.10. Intellia Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was €-2.98. Intellia Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Intellia Therapeutics  (STU:38I) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Intellia Therapeutics Cyclically Adjusted FCF per Share Related Terms


Intellia Therapeutics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Intellia Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Intellia Therapeutics Cyclically Adjusted FCF per Share Chart

Intellia Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -2.25 -2.37

Intellia Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.26 -2.28 -2.37 -2.46 -2.98

STU:38I vs RXRX, SEPN, DMRA: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Intellia Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intellia Therapeutics Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Intellia Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Intellia Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


STU:38I
69GF Score
Intellia Therapeutics Inc STU:38I
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Intellia Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Intellia Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.552/333.9520*333.9520
=-0.552

Current CPI (Jun. 2026) = 333.9520.

Intellia Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 -0.213 241.428 -0.295
201612 -0.469 241.432 -0.649
201703 -0.419 243.801 -0.574
201706 -0.432 244.955 -0.589
201709 -0.457 246.819 -0.618
201712 -0.511 246.524 -0.692
201803 -0.378 249.554 -0.506
201806 -0.468 251.989 -0.620
201809 -0.287 252.439 -0.380
201812 -0.201 251.233 -0.267
201903 -0.450 254.202 -0.591
201906 -0.553 256.143 -0.721
201909 -0.509 256.759 -0.662
201912 -0.570 256.974 -0.741
202003 -0.706 258.115 -0.913
202006 0.938 257.797 1.215
202009 -0.423 260.280 -0.543
202012 -0.553 260.474 -0.709
202103 -0.685 264.877 -0.864
202106 -0.681 271.696 -0.837
202109 -0.802 274.310 -0.976
202112 -0.684 278.802 -0.819
202203 -1.531 287.504 -1.778
202206 -1.111 296.311 -1.252
202209 -1.099 296.808 -1.237
202212 -1.016 296.797 -1.143
202303 -1.204 301.836 -1.332
202306 -0.990 305.109 -1.084
202309 -1.117 307.789 -1.212
202312 -0.959 306.746 -1.044
202403 -1.187 312.332 -1.269
202406 -0.567 314.175 -0.603
202409 -0.768 315.301 -0.813
202412 -0.808 315.605 -0.855
202503 -1.338 319.799 -1.397
202506 -0.835 322.561 -0.864
202509 -0.595 324.800 -0.612
202512 -0.511 324.054 -0.527
202603 -0.857 330.213 -0.867
202606 -0.552 333.952 -0.552

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-2.98 mean?
Intellia Therapeutics (STU:38I) has a Cyclically Adjusted FCF per Share of €-2.98 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Intellia Therapeutics and its competitors.
Is Intellia Therapeutics' Cyclically Adjusted FCF per Share too high?
Intellia Therapeutics' current Cyclically Adjusted FCF per Share is €-2.98. Overall, Intellia Therapeutics has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Intellia Therapeutics' Cyclically Adjusted FCF per Share compare to RXRX and SEPN?
Intellia Therapeutics' Cyclically Adjusted FCF per Share of €-2.98 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Intellia Therapeutics and its competitors. Intellia Therapeutics's current Cyclically Adjusted FCF per Share is €-2.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intellia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Intellia Therapeutics (STU:38I) is currently considered Modestly Undervalued. The stock's GF Value™ is €11.36, compared to a current price of €10.10 — trading 11.1% below its estimated fair value. The current Cyclically Adjusted FCF per Share is €-2.98. Intellia Therapeutics' overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Intellia Therapeutics (STU:38I), the current Cyclically Adjusted FCF per Share is €-2.98 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Intellia Therapeutics (STU:38I) Overvalued in 2026?

Based on GuruFocus' analysis, Intellia Therapeutics stock appears to be undervalued. The current stock price of €10.10 is trading 11.1% below its estimated GF Value™ of €11.36. GuruFocus considers Intellia Therapeutics to be Modestly Undervalued.

Key valuation signals for STU:38I:

  • Cyclically Adjusted FCF per Share: €-2.98
  • GF Value™: €11.36 vs. price of €10.10 (11.1% below fair value)
  • GF Score™: 69/100 with 5 warning signs

No single metric tells the full story. See the STU:38I stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Intellia Therapeutics Business Description

Other Exchanges NTLA:USA0JBU:UK
Address 40 Erie Street, Suite 130, Cambridge, MA, USA, 02139
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
69GF Score

Get the complete analysis for STU:38I

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€10.10
Price
€11.36
GF Value